Semen Analysis Parameters Following Pfizer’s COVID-19 Vaccine

Overview

In this study the investigators will explore the effect of the BNT162b2 COVID-19 Vaccine on semen analysis parameters among 75 fertile men. Fertile men will be regarded as such if they previously successfully impregnated their partners without the use of artificial reproductive technology, or men who previously had a normal sperm analysis exam by WHO criteria (2010). Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. In addition, the participants will fill a brief questionnaire with information regarding their medical and reproductive history. The investigators will examine the macroscopic and microscopic properties of the semen samples and compare them to the WHO semen analysis reference range in an attempt to ascertain whether the vaccine influences sperm parameters.

Full Title of Study: “The Effect of BNT162b2 mRNA COVID-19 Vaccine on Semen Analysis Parameters Among 75 Fertile Men”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 10, 2021

Detailed Description

The 2019 novel coronavirus disease (COVID-19) is a highly infectious respiratory tract disease which was first reported in Wuhan, Hubei Province, China in Dec 2019, but has since spread globally. By march 2020 it was declared by WHO as a public health emergency pandemic and has thus far affected tens of millions worldwide. The implications of COVID 19 infection on male fertility were examined in a previous study, which found decreased sperm concentration in recovering patients compared with controls. The newly available mRNA COVID 19 vaccine by Pfizer was recently evaluated in a large multicenter placebo controlled RCT. The vaccine is comprised of BNT162b2, a lipid nanoparticle formulated nucleoside-modified RNA (modRNA) encoding the SARS-CoV2 full length spike protein, modified by two Proline mutations. The two 20 µg doses were shown to elicit high SARS-COV2 neutralizing antibody titers alongside high antigen specific CD8+ and Th1 type CD4+ T cell response. It was subsequently shown to be 95% effective in preventing COVID-19 infection a week following the second dose with a favorable safety profile in a 2-month median following up time. Unfounded claims in the popular media linked a possible correlation between the COVID-19 vaccine and potential femalemale infertility. Currently. there is no information in the medical literature which examined semen analysis parameters following the COVD-19 vaccine. In this study the investigators will explore the effect of the BNT162b2 COVID-19 Vaccine on semen analysis parameters among 75 fertile men. Fertile men will be regarded as such if they previously successfully impregnated their partners without the use of artificial reproductive technology, or men who previously had a normal sperm analysis exam by WHO criteria (2010). Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. In addition, the participants will fill a brief questionnaire with information regarding their medical and reproductive history. The investigators will examine the macroscopic and microscopic properties of the semen samples and compare them to the WHO semen analysis reference range in an attempt to ascertain whether the vaccine influences sperm parameters.

Interventions

  • Other: Sperm collection
    • Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.

Arms, Groups and Cohorts

  • Vaccinated Men
    • Fertile men who were vaccinated with the BNT162b2 COVID-19 Vaccine

Clinical Trial Outcome Measures

Primary Measures

  • Sperm Concentration (10^6/ml)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Semen concentration (10^6/ml)
  • Sperm Motility (%)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Sperm percentage with proper forward progression
  • White Blood Cells (10^6/ml) in Semen
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Amount of white blood cells (10^6/ml) in semen
  • Sperm Morphology (%)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Sperm morphology (%)
  • Sperm Vitality (%)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Sperm vitality (%)
  • Semen Liquefaction (normal/abnormal)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Macroscopic appearance – Semen liquefaction appearance
  • Semen Viscosity (normal/abnormal)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Macroscopic appearance – Semen viscosity appearance
  • Semen Color
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Macroscopic appearance – Semen color appearance
  • Semen PH
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Semen PH
  • Semen Volume (ml)
    • Time Frame: 1-2 months after the second COVID-19 vaccine
    • Semen Volume (ml)

Participating in This Clinical Trial

Inclusion Criteria

  • Previously impregnated their partner without the use of assisted reproduce technology, or previously had a normal sperm analysis exam by WHO 2010 criteria. – 1-2 months following the second dose of BNT162b2 COVID-19 Vaccine. Exclusion Criteria:

  • Known abnormal semen parameters. – Age above 45.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sheba Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Jigal Haas MD, Senior Gynecologist and Obstetrician – Sheba Medical Center
  • Overall Contact(s)
    • Jigal Haas, MD, 972-54-6975372, jigal.haas@sheba.health.gov.il

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.